Saturday 12.10.2013

Hematology Educational Workshop Satellite Symposium Scientific Session Main Program
Session details 08:30–13:45
Hematology Educational

Hematology Educational

Room:Pipin II (Dorint Hotel)
Session details 10:00–11:30
Workshop 1 (Parallel Sessions)

Prognostic and biomarkers – tissue and serum / plasma

Room:Pipin II (Dorint Hotel)
  • 10:00

    The immunomodulatory and angiogenic protein Galectin 1 is a circulating biomarker in Hodgkin Lymphoma

  • Plasma TARC as a treatment response marker and prognostic tissue biomarkers in classical Hodgkin Lymphoma

  • Prognostic biomarkers from gene expression pro ling in formalin- xed para n-embedded biopsies

  • Flow cytometry studies of lymphocyte predominant cells from nodular Lymphocyte Predominant Hodgkin Lymphoma

  • Identication of CD8 ‘follicularcytotoxic’ cells in tumor infiltrating T cells from classical Hodgkin Lymphoma

Session details 10:00–11:30
Workshop 2 (Parallel Sessions)

Closed workshop for pediatric groups

Room:Sandkaul (Dorint Hotel)
  • 10:00

    Overview of international harmonization of staging and response criteria in pediatric Hodgkin Lymphoma – summary of results thus far

  • Highlights and controversies found between existing major pediatric groups

  • Discussion

Session details 12:00–13:30
Workshop 3 (Parallel Sessions)

GHSG Workshop

Room:Martin & Augustin (Dorint Hotel)
Session details 12:00–13:30
Workshop 4 (Parallel Sessions)

Radiotherapy of Hodgkin Lymphoma in 2013

Room:Pipin II (Dorint Hotel)
  • 12:00

    New concepts of eld and dose: Implications for disease control and long-term outcome

  • The role of radiotherapy in early stage and the relevance of PET response

  • Is radiotherapy still relevant for patients with advanced stage disease and in salvage of chemotherapy failures?

Session details 12:00–13:30
Workshop 5 (Parallel Sessions)

Challenges in the development of new drugs in HL

Room:Severin (Dorint Hotel)
  • 12:00

    Progress on new drug development in Hodgkin Lymphoma

  • Clinical trials design, response assessment, and trial end points

  • Challenges of translation of abundant new data into clinical trials in rare diseases

  • Challenges of preclinical models

Session details 14:00–15:30
Workshop 6 (Parallel Sessions)

New technologies for improving the therapeutic ratio of RT in HL

Room:Pipin II (Dorint Hotel)
Session details 14:00–15:30
Workshop 7 (Parallel Sessions)

PET

Room:Pipin I (Dorint Hotel)
  • 14:00

    The new NCCN guidelines and the role of PET / CT

  • Imaging and PET / CT recommendations for the revised staging and response criteria

  • Metabolic tumor volume and other new concepts

  • qPET – a quantitative approach to assess response in interim FDG-PET scans in lymphoma

Session details 14:00–15:30
Workshop 8 (Parallel Sessions)

Somatic aberrations, epigenetic mechanisms and deregulated gene expression

Room:Severin (Dorint Hotel)
  • 14:00

    Novel and recurrent coding sequence mutations in microdissected Hodgkin-/ Reed- Sternberg cells

  • No chance for a comeback? The multiple ways to block the B-cell phenotype in Hodgkin Lymphoma

  • New insights into the transcription factor network of Hodgkin-/ Reed-Sternberg cells

  • Transcriptome analysis of Hodgkin and Reed-Sternberg cells enriched from Hodgkin Lymphoma biopsies: an approach to virus discovery

  • Downregulation of FOXO1 prevents induction of the tumor suppressor PRDM1 in cHL

Session details 16:00–17:30
Workshop 9 (Parallel Sessions)

Integrating PET into the management of early stage HL

Room:Pipin I (Dorint Hotel)
  • 16:00

    Introduction

  • RAPID trial: Update and lessons in standardized interpretation of PET

  • BCCA experience: Population-based PET guided treatment

  • Challenges applying PET for early stage disease

  • What did EORTC H10 teach us?

  • Formulation of conclusions and identi cation of important outstanding questions

Session details 16:00–17:30
Workshop 10 (Parallel Sessions)

International Guidelines on Follow-up and Survivorship

Room:Martin & Augustin (Dorint Hotel)
  • 16:00

    Some “philosophical” introductoryremarkson the need and pitfalls of long-term follow-up

  • The ASCO and the Dutch guidelines

  • Minimizing treatment and its consequences for long term toxicity and follow-up

  • Reducing RT to involved node principle and its consequences for long-term toxicity and follow-up

  • General discussion

Session details 16:00–17:30
Workshop 11 (Parallel Sessions)

Genetic predisposition – HLA, GWAS, secondary malignancies, prognostic

Room:Severin (Dorint Hotel)
  • 16:00

    Familial risks and germline genetics of Hodgkin Lymphoma

  • HLA locus and risk of Hodgkin Lymphoma

  • Multiple neoplasias a er Hodgkin Lymphoma; incidence and risk factors

  • Genetic defects of T-cell function predisposing for EBV-associated lymphoproliferation and Hodgkin Lymphoma

  • General discussion

Session details 18:00–19:00
Workshop 12

Targeted Therapy: The Future in the Treatment of Malignant Lymphoma

Room:Pipin I (Dorint Hotel)
  • 18:00

    New approaches in the treatment of mantle cell and other Non Hodgkin Lymphoma

  • New horizons in the treatment o CLL

Sunday 13.10.2013

Hematology Educational Workshop Satellite Symposium Scientific Session Main Program
Session details 07:30–08:30
Satellite Symposium

Novel Methodology to aid in the Diagnosis of Difficult Hodgkin Lymphoma Cases

Room:Großer Saal
  • 07:30

    Introduction and Perspective

  • Novel methodology to aid in the diagnosis of di cult lymphoma cases

  • Case Series Presentation using MultiOmyx Methodology

  • Questions & Answers

Session details 08:30–10:00
Scientific Session 1

Interactive Case Discussions

Room:Großer Saal
Session details 10:30–12:00
Scientific Session 2

Pathways

Room:Großer Saal
  • 10:30

    JAK / STAT

  • Non-coding RNA and tumor cell survival

  • CSF1 and CSF1R

  • Integrated genomic analysis of ow sorted Hodgkin and Reed-Sternberg cell in primary classical Hodgkin Lymphoma

  • TCF3 / E2A (19p13.3) is a novel Hodgkin Lymphoma susceptibility locus; a meta-GWAS study from the InterLymph Hodgkin Lymphoma consortium

  • Hodgkin-Reed-Sternberg cells in classical Hodgkin Lymphoma show alterations of genes encoding the NADPH oxidase complex and impaired reactive oxygen species synthesis capacity

Session details 12:15–13:45
Satellite Symposium

Lenalidomide in Lymphoma – Latest Update on Clinical Data

Room:Großer Saal
  • 12:15

    Rationale and Clinical Experience with Lenalidomide in Hodgkin Lymphoma

  • Progress in the treatment of Aggressive B-Cell Lymphomas

  • Emerging treatment options for mantle cell lymphoma

Session details 14:00–15:15
Satellite Symposium

New Insights in the Treatment and Management of Lymphoid Malignancies

Room:Großer Saal
  • 14:00

    New Aspects on Dose Density in Malignant Lymphoma

  • The impact of hematological toxicity in Hodgkin Lymphoma

  • Bispeci c CD19 antibodies – a new treatment principle for management of relapsed / refractory ALL and NHL

Session details 16:00–17:30
Satellite Symposium

Relapsed/Refractory Hodgkin Lymphoma: Exploring Targeted Therapeutic Options

Room:Großer Saal
  • 16:00

    Welcome and Introduction

  • The challenge of relapsed Hodgkin Lymphoma in the era of contemporary therapy

  • Q&A

  • Defining the ideal target in Hodgkin Lymphoma

  • Q&A

  • Targeting CD30 with monoclonal antibody- based constructs

  • Q&A

  • Current success and future opportunities with targeted therapy in Hodgkin Lymphoma

  • Q&A

  • Closing comments

Session details 18:00–20:00
Main Program

Opening Ceremony

Room:Großer Saal
  • 18:00

    Bonadonna Lecture: The Hodgkin puzzle: Are we getting close?

  • Awards Ceremony

Session details 20:00
Main Program

Get Together

Room:Weinkeller

Monday 14.10.2013

Hematology Educational Workshop Satellite Symposium Scientific Session Main Program
Session details 07:30–08:30
Satellite Symposium

Beyond the revolution of MabThera

Room:Großer Saal
Session details 08:30–10:00
Scientific Session 3

Biology and Microenvironment

Room:Großer Saal
  • 08:30

    Microenvironment in Hodgkin Lymphoma

  • Molecular pathogenesis of Hodgkin Lymphoma

  • Deregulation of di erentiation in pathogenesis of cHL

  • Plasma microRNA are disease response biomarkers in classical Hodgkin Lymphoma

  • CD57+ T cells in nodular lymphocyte predominant Hodgkin Lymphoma are T-follicular helper cells

  • Analysis of myeloid suppressor marker Arginase identi es CD68+ / Arginase+ myeloid / monocytic subsets and exerts stronger prognostic in uence than macrophage quanti cation in Classical Hodgkin Lymphoma

Session details 10:30–12:00
Scientific Session 4

Early Stages

Room:Großer Saal
  • 10:30

    Update on the NCRI RAPID trial

  • An update on the EORTC / LYSA / FIL H10 trial

  • WS report and further optimization in early stage Hodgkin Lymphoma

  • Impact of bleomycin and dacarbazine within the ABVD regimen in the treatment of early-stage favorable Hodgkin Lymphoma: Final results of the GHSG HD13 trial

  • De nition of bulky disease in early stage Hodgkin Lymphoma in computed tomography era: Prognostic signi cance of measurements in the coronal and transverse planes

  • Brentuximab vedotin plus AVD as initial therapy of non-bulky limited stage classical Hodgkin Lymphoma: Interim analysis of an ongoing phase II trial

Session details 12:15–13:45
Satellite Symposium

NHL and G-CSF – Focus on optimising the results

Room:Großer Saal
Session details 14:00–15:30
Scientific Session 5

Hodgkin lymphoma in older patients

Room:Großer Saal
  • 14:00

    Epidemiology and biology

  • First line treatment

  • Relapsed / refractory Hodgkin Lymphoma in older patients

  • GHSH phase I / II trial of AVD-Rev (adriamycin, vinblastin, dacarbacine and lenalidomide) for older Hodgkin Lymphoma patients

  • Sequential brentuximab vedotin (BV) and adriamycin, vinblastine, and dacarbazine (AVD) for older patients with untreated Hodgkin Lymphoma (HL): Preliminary toxicity ndings from a phase II window study

  • Treatment outcome in 111 elderly patients with Hodgkin Lymphoma: a retrospective analysis

Session details 15:45–17:30
Scientific Session 6

PET and prediction

Room:Großer Saal
  • 15:45

    PET for early response prediction

  • PET review in GHSG trials

  • PETinrelapsedorrefractoryHodgkinLymphoma

  • Response-adapted therapy of stage III-IV Hodgkin lymphoma based on interim FDG-PET imaging: early results of US intergroup S0816

  • Very early response as measured by (18F)- uorodeoxyglucose-positron emission tomography (FDG-PET) a er one cycle of chemotherapy in newly diagnosed pediatric / adolescent low risk Hodgkin Lymphoma (HL)

  • Tailored therapy in Hodgkin Lymphoma, based on prede ned risk factors and early interim PET / CT, Israeli H2 protocol: Preliminary report on 317 patients

Session details 17:45–19:15
Satellite Symposium

Defining Therapeutic Targets in T-Cell Lymphoma

Room:Großer Saal
  • 17:45

    Welcome and Introduction

  • Traditional Approaches to T-cell Lymphoma

  • Q&A

  • Transition with targeted agents in T-cell Lymphoma

  • Q&A

  • Targeting CD30 in T-cell Lymphoma

  • Q&A

  • Challenging the experts: An interactive panel discussion

  • Adjourn

Tuesday 15.10.2013

Hematology Educational Workshop Satellite Symposium Scientific Session Main Program
Session details 07:30–09:00
Workshop 13

Beyond the International Harmonization Criteria – New challenges in the application of imaging techniques for staging and response

Room:Großer Saal
  • 07:30

    Practical experience in the application of the International Harmonization Criteria – as viewed by a medical oncologist

  • Anatomic imaging challenges of the International Harmonization Criteria

  • Nuclear medicine aspects of the International Harmonization Criteria, as they apply to pediatrics

  • Overview of the challenges encountered by the Pediatric International Harmonization Criteria Workshop

  • Discussion

Session details 09:00–10:30
Scientific Session 7

Survivorship

Room:Großer Saal
Session details 11:00–12:30
Scientific Session 8

Advanced Stages

Room:Großer Saal
  • 11:00

    Risk-adapted therapy in advanced stage Hodgkin Lymphoma: An Update

  • Can we improve ABVD?

  • Can we improve BEACOPP?

  • Impact of dose reductions of bleomycin and vincristine in patients with advanced Hodgkin Lymphoma treated with BEACOPP polychemotherapy: A comprehensive analysis of the German Hodgkin Study Group (GHSG) HD12 and HD15 trials

  • Standard ABVD vs. escalated BEACOPP in stage III – IV low risk Hodgkin Lymphoma (IPS 0-2): the Lymphoma Study Association (LYSA) H34 trial

  • Response rates and toxicity of response-adapted therapy in advanced Hodgkin Lymphoma: initial results from the international RATHL study

Session details 12:45–14:15
Satellite Symposium

Update on Infectious Diseases in Hematology Patients

Room:Großer Saal
  • 12:45

    Introduction

  • Clinical infectious challenges in patients with Hodgkin Lymphoma

  • Present and upcoming vaccines for the immunocomprised host

  • Focussing on unmet medical needs in abdominal infections

  • Discussion and Summary

Session details 13:45–14:15
Main Program

Poster Walk

Room:Kleiner Saal
Session details 14:30–16:00
Scientific Session 9

Relapsed

Room:Großer Saal
  • 14:30

    What’s new in relapsed Hodgkin Lymphoma?

  • Debate: Is there still a role for allogeneic TX in Hodgkin Lymphoma?

  • Phase 2 study everolimus for relapsed / refractory classical Hodgkin Lymphoma (cHL)

  • Outcome of patients treated with autologous stem-cell transplantation for rst relapsed or refractory Hodgkin Lymphoma: A long-term analysis of the prospective LYSA / SFGM-TC H96 trial

  • PET adapted sequential salvage therapy with brentuximab vedotin and augmented ICE for transplant eligible patients with relapsed and refractory Hodgkin Lymphoma

Session details 16:15–18:00
Scientific Session 10

Milestones in Hodgkin Lymphoma

Room:Großer Saal
Session details 20:00
Main Program

Closing Remakrs

Room:Großer Saal

Basement

Allocations

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Floor plan of Basement Wardrobe Go to Ground Floor Go to Ground Floor Weinkeller Basement

Ground Floor

Allocations

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Floor plan of Ground Floor Go to Basement Go to Basement Go to First Floor Go to First Floor Go to Ground Level Kleiner Saal Ground Floor

First Floor

Allocations

  • Room details Großer Saal

    Main Program, Satellite Symposia, Workshop

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Floor plan of First Floor Go to Ground Floor Go to Ground Floor Großer Saal First Floor

Dorint Hotel: Ground Level

Allocations

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Floor plan of Dorint Hotel: Ground Level Go to Ground Floor Go to Ground Floor Go to First Floor Pipin II Sandkaul Pipin I Dorint Hotel: Ground Level

Dorint Hotel: First Floor

Allocations

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Floor plan of Dorint Hotel: First Floor Go to Ground Level Martin & Augustin Severin Dorint Hotel: First Floor

Exhibition

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Map of the exhibition. Map of the First Floor showing the location of 0 exhibitors. Stair to Ground Floor Stair to Ground Floor Großer Saal

Acknowledgements

Academic Partners

Not Found

Back to start